Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer seeking Geodon label change

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer's Jan. 22 Geodon (ziprasidone) supplemental NDA seeks to include the drug's "lack of adverse effects on blood lipids and glycemic control" in labeling. The filing suggests Pfizer was successful in convincing FDA not to add an atypical antipsychotic class warning on the risk of diabetes. Pfizer submitted a proposal for the addition of "Geodon's metabolic advantages" instead of FDA's requested warning Nov. 24, 2003. The sNDA may be aided by a Jan. 27 statement from the American Diabetes Association that patients on Geodon and Bristol-Myers Squibb/Otsuka's Abilify (aripiprazole) are not at increased risk of diabetes. Lilly (Zyprexa), Janssen (Risperdal) and AstraZeneca (Seroquel) have all modified labeling per FDA's September 2003 request. Pfizer's sNDA is also looking to add "greater initial dosing flexibility" and modify labeling on Geodon's effect on heart rhythm, "providing a new perspective on the clinical relevance of this effect," the firm says. Labeling currently carries an extensive bolded warning on QT prolongation...

You may also be interested in...



Grail Starts PATHFINDER Trial To Evaluate Multi-Cancer Blood Test For Early Cancer Detection

Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Topics

UsernamePublicRestriction

Register

PS002467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel